Literature DB >> 31881245

Lyn regulates creatine uptake in an imatinib-resistant CML cell line.

Denis O Okumu1, Lucas J Aponte-Collazo1, Brian J Dewar2, Nathan J Cox3, Michael P East1, Katherine Tech2, Ian M McDonald1, Andrey P Tikunov2, Ekhson Holmuhamedov4, Jeffrey M Macdonald2, Lee M Graves5.   

Abstract

BACKGROUND: Imatinib mesylate (imatinib) is the first-line treatment for newly diagnosed chronic myeloid leukemia (CML) due to its remarkable hematologic and cytogenetic responses. We previously demonstrated that the imatinib-resistant CML cells (Myl-R) contained elevated Lyn activity and intracellular creatine pools compared to imatinib-sensitive Myl cells.
METHODS: Stable isotope metabolic labeling, media creatine depletion, and Na+/K+-ATPase inhibitor experiments were performed to investigate the origin of creatine pools in Myl-R cells. Inhibition and shRNA knockdown were performed to investigate the specific role of Lyn in regulating the Na+/K+-ATPase and creatine uptake.
RESULTS: Inhibition of the Na+/K+-ATPase pump (ouabain, digitoxin), depletion of extracellular creatine or inhibition of Lyn kinase (ponatinib, dasatinib), demonstrated that enhanced creatine accumulation in Myl-R cells was dependent on uptake from the growth media. Creatine uptake was independent of the Na+/creatine symporter (SLC6A8) expression or de novo synthesis. Western blot analyses showed that phosphorylation of the Na+/K+-ATPase on Tyr 10 (Y10), a known regulatory phosphorylation site, correlated with Lyn activity. Overexpression of Lyn in HEK293 cells increased Y10 phosphorylation (pY10) of the Na+/K+-ATPase, whereas Lyn inhibition or shRNA knockdown reduced Na+/K+-ATPase pY10 and decreased creatine accumulation in Myl-R cells. Consistent with enhanced uptake in Myl-R cells, cyclocreatine (Ccr), a cytotoxic creatine analog, caused significant loss of viability in Myl-R compared to Myl cells.
CONCLUSIONS: These data suggest that Lyn can affect creatine uptake through Lyn-dependent phosphorylation and regulation of the Na+/K+-ATPase pump activity. GENERAL SIGNIFICANCE: These studies identify kinase regulation of the Na+/K+-ATPase as pivotal in regulating creatine uptake and energy metabolism in cells.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  (1)H NMR spectroscopy; Apoptosis; Cell viability; Chronic myelogenous leukemia; Creatine; Creatine transporter; Cyclocreatine; Drug resistance; Imatinib; Kinase; Lyn; Metabolites; Metabolomics; Phosphocreatine; Ponatinib; Sodium/potassium-ATPase

Mesh:

Substances:

Year:  2019        PMID: 31881245      PMCID: PMC7055176          DOI: 10.1016/j.bbagen.2019.129507

Source DB:  PubMed          Journal:  Biochim Biophys Acta Gen Subj        ISSN: 0304-4165            Impact factor:   3.770


  58 in total

1.  Kinetics of cyclocreatine and Na(+) cotransport in human breast cancer cells: mechanism of activity.

Authors:  N Maril; H Degani; E Rushkin; A D Sherry; M Cohn
Journal:  Am J Physiol       Date:  1999-10

2.  Creatine uptake, metabolism, and efflux in human monocytes and macrophages.

Authors:  J D Loike; M Somes; S C Silverstein
Journal:  Am J Physiol       Date:  1986-07

3.  Glucose transport regulation by p210 Bcr-Abl in a chronic myeloid leukaemia model.

Authors:  J Bentley; I Walker; E McIntosh; A D Whetton; P J Owen-Lynch; S A Baldwin
Journal:  Br J Haematol       Date:  2001-01       Impact factor: 6.998

4.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

5.  Assignment of the creatine transporter gene (SLC6A8) to human chromosome Xq28 telomeric to G6PD.

Authors:  P Gregor; S R Nash; M G Caron; M F Seldin; S T Warren
Journal:  Genomics       Date:  1995-01-01       Impact factor: 5.736

6.  The cloning and expression of a human creatine transporter.

Authors:  I Sora; J Richman; G Santoro; H Wei; Y Wang; T Vanderah; R Horvath; M Nguyen; S Waite; W R Roeske
Journal:  Biochem Biophys Res Commun       Date:  1994-10-14       Impact factor: 3.575

7.  Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Authors:  M E Gorre; M Mohammed; K Ellwood; N Hsu; R Paquette; P N Rao; C L Sawyers
Journal:  Science       Date:  2001-06-21       Impact factor: 47.728

Review 8.  Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.

Authors:  Jane F Apperley
Journal:  Lancet Oncol       Date:  2007-11       Impact factor: 41.316

9.  Phosphocreatine protects against LPS-induced human umbilical vein endothelial cell apoptosis by regulating mitochondrial oxidative phosphorylation.

Authors:  Zhengwu Sun; Xiaoyan Lan; Anil Ahsan; Yalin Xi; Shumin Liu; Zonghui Zhang; Peng Chu; Yushu Song; Fengyuan Piao; Jinyong Peng; Yuan Lin; Guozhu Han; Zeyao Tang
Journal:  Apoptosis       Date:  2016-03       Impact factor: 4.677

10.  Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study.

Authors:  J Klawitter; N Anderson; J Klawitter; U Christians; D Leibfritz; S G Eckhardt; N J Serkova
Journal:  Br J Cancer       Date:  2009-03-03       Impact factor: 7.640

View more
  3 in total

1.  Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake.

Authors:  Vusumuzi N Hove; Kenneth Anderson; Elizabeth R Hayden; Kyle Z Pasquariello; Alice A Gibson; Shichen Shen; Jun Qu; Yan Jin; Jeffrey C Miecznikowski; Shuiying Hu; Jason A Sprowl
Journal:  Mol Pharmacol       Date:  2022-04-05       Impact factor: 4.054

Review 2.  Creatine Supplementation for Patients with Inflammatory Bowel Diseases: A Scientific Rationale for a Clinical Trial

Authors:  Theo Wallimann; Caroline H T Hall; Sean P Colgan; Louise E Glover
Journal:  Nutrients       Date:  2021-04-23       Impact factor: 5.717

3.  Plasma creatine concentration is associated with incident hypertension in a cohort enriched for the presence of high urinary albumin concentration: the Prevention of Renal and Vascular Endstage Disease study.

Authors:  Adrian Post; Daan Kremer; J Casper Swarte; Sara Sokooti; Fabian A Vogelpohl; Dion Groothof; Ido P Kema; Erwin Garcia; Margery A Connelly; Theo Wallimann; Robin P F Dullaart; Casper F M Franssen; Stephan J L Bakker
Journal:  J Hypertens       Date:  2022-02-01       Impact factor: 4.844

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.